Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
Brian G Feagan, Bruce E Sands, William J Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julián Panés, Alexander Tkachev, Dilara Kalimullina, Robert Petryka, Marina Osipenko, Nataliia Tsarynna, Leonid Bilianskyi, Dariusz Kleczkowski, Andrii Yurkiv, Marek Woynarowski, Orest Abrahamovych, Olha Ivanishyn, Grazyna Rydzewska, Jaroslaw Kierkus, Elina Petrova, Olga Vasilevskaya, Halyna Afanasieva, Carlos Francesconi, Jaroslaw Leszczyszyn, Elena Bunkova, Dmitry Platonov, Olena Datsenko, Oleksii Gridnyev, Ihor Hospodarsky, Liudmyla Prystupa, Mykola Stanislavchuk, Anatoly Pershko, Oksana Shchukina, Vladimir Simanenkov, Oleksandr Golovchenko, William Holderman, Juan Lasa, Jakob Begun, Maria de Lourdes de Abreu Ferrari, Pedro Lopez, Andrey Obrezan, Shiraz Farooq, Felix Tiongco, Abel Novillo, Emiliano Tron, Finlay Macrae, Rupert Leong, Ligia Yukie Sassaki, Cyrla Zaltman, Roberto Kaiser Junior, Andreas Stallmach, Jochen Klaus, Manuel Martinez, Azalia Ruiz, Rustem Abdulkhakov, Vishvinder Sharma, Louis Korman, James Lord, Bhaktasharan Patel, Timothy Ritter
Source record
Source: Crossref
Published: Apr 1, 2023
DOI: 10.1016/s2468-1253(22)00427-7
Open original source ↗Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.